Literature DB >> 1474330

Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys.

M Dukes1, D Miller, A E Wakeling, J C Waterton.   

Abstract

ICI 182,780 is a potent specific pure antioestrogen which may offer advantages in breast cancer treatment compared with partial agonists like tamoxifen. To characterize further the potency and efficacy of ICI 182,780, its effects on the uterus of ovariectomized, oestrogen-treated monkeys (Macaca nemestrina) have been measured using magnetic resonance imaging (MRI). Quantitative MRI allows accurate non-invasive repetitive measurements of endometrial and myometrial volume following hormonal treatments, using each animal as its own control. Single i.m. injections of a long-acting oil-based formulation of ICI 182,780 sustained blockade of oestradiol action on the monkey uterus in a dose-dependent manner for 3-6 weeks. Repeated injections of 4 mg ICI 182,780/kg at 4-weekly intervals provided increasingly effective blockade of uterine proliferation. In a short-acting formulation, ICI 182,780 also completely blocked the trophic action of oestradiol, administered concurrently, in ovariectomized monkeys. Similarly, ICI 182,780 caused involution of the uterus stimulated by prior treatment with oestradiol. The rate and extent of uterine involution in monkeys treated with ICI 182,780 was similar to that seen following oestrogen withdrawal. These studies demonstrate that ICI 182,780 is a fully effective pure antioestrogen in a primate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1474330     DOI: 10.1677/joe.0.1350239

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

Review 1.  Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 2.  Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Authors:  Kate McKeage; Monique P Curran; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  The future of new pure antiestrogens in clinical breast cancer.

Authors:  A E Wakeling
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.

Authors:  Aysegül Kaymak; Sergi Sayols; Thaleia Papadopoulou; Holger Richly
Journal:  Oncotarget       Date:  2018-06-19

Review 5.  Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Authors:  C K Osborne; A Wakeling; R I Nicholson
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

6.  A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.

Authors:  S Addo; R A Yates; A Laight
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.